Medical News

August 26, 2004 — Research and Markets announces the addition of Psoriasis Therapeutics 2004 to its offerings.

With the worldwide prevalence of psoriasis estimated at nearly 14 million people in 2004, there is increasing demand for therapeutics that control disease symptoms with greater efficacyand longer time duration, treat the disease on a much more comprehensive level, and improve the quality of life for patients.

The worldwide psoriasis therapeutics market is estimated to reach $1.085B in 2004 and will continue to grow at a compound annual rate of 23.6% to reach approximately 3.12B worldwide by 2009. Growth will be driven by the introduction of several biologic immunosuppressivesalong with Amgen?s currently available Enbrel, BiogenIdec?s Amevive, and Genentechand XOMA?sRaptiva.

This report includes in-depth analysis on physician perspectives and incorporates an assessment of clinical usefulness and strength of current market players to competitively benchmark products that will reach the market by the end of 2009. In addition, the study provides the financial analysis and detailed assumptions used to determine major company market shares and to estimate the industry-wide revenue forecast.

For a thorough analysis of this market, the report:
- evaluates leading current and emerging therapeutics
- assesses the results of a 15 physician panel survey and examines their usage of current treatments and attitudes toward emerging therapeutics
- provides a market forecast and revenue model from 2004 through 2009 with detailed revenue assumptions for each therapeutic as well as the industry as a whole
- analyzes the strategic positioning of 8 emerging psoriasis therapeutics

For a complete index of this report click on http://www.researchandmarkets.com/reports/222284

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

August 26, 2004 — Research and Markets announces the addition of Psoriasis Therapeutics 2004 to its offerings.

With the worldwide prevalence of psoriasis estimated at nearly 14 million people in 2004, there is increasing demand for therapeutics that control disease symptoms with greater efficacyand longer time duration, treat the disease on a much more comprehensive level, and improve the quality of life for patients.

The worldwide psoriasis therapeutics market is estimated to reach $1.085B in 2004 and will continue to grow at a compound annual rate of 23.6% to reach approximately 3.12B worldwide by 2009. Growth will be driven by the introduction of several biologic immunosuppressivesalong with Amgen?s currently available Enbrel, BiogenIdec?s Amevive, and Genentechand XOMA?sRaptiva.

This report includes in-depth analysis on physician perspectives and incorporates an assessment of clinical usefulness and strength of current market players to competitively benchmark products that will reach the market by the end of 2009. In addition, the study provides the financial analysis and detailed assumptions used to determine major company market shares and to estimate the industry-wide revenue forecast.

For a thorough analysis of this market, the report:
- evaluates leading current and emerging therapeutics
- assesses the results of a 15 physician panel survey and examines their usage of current treatments and attitudes toward emerging therapeutics
- provides a market forecast and revenue model from 2004 through 2009 with detailed revenue assumptions for each therapeutic as well as the industry as a whole
- analyzes the strategic positioning of 8 emerging psoriasis therapeutics

For a complete index of this report click on http://www.researchandmarkets.com/reports/222284

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com